XTRA:BAYNPharmaceuticals
Will OCEANIC-STROKE’s Asundexian Data Shift Bayer’s (XTRA:BAYN) Narrative on Innovation and Risk?
In early February 2026, Bayer reported pivotal Phase III OCEANIC-STROKE results showing its investigational Factor XIa inhibitor asundexian reduced recurrent ischemic stroke without increasing major bleeding versus placebo, both on top of antiplatelet therapy.
A key insight from OCEANIC-STROKE is that asundexian delivered stroke risk reduction across all enrolled TOAST stroke subtypes, while maintaining a bleeding profile comparable to placebo.
Against this backdrop, we’ll examine how the...